Abstract
Abstract: Obesity is a severe health problem worldwide due to its association with various adverse health consequences. The present study aims to evaluate the anti-obesity effects of resveratrol, as a natural polyphenol, on the 3T3-L1 adipocytes. PubMed, Scopus, ScienceDirect, Web of Sciences, and Google Scholar databases were searched up to March 2022 using relevant keywords. All original articles, written in English, evaluating the anti-obesity effects of resveratrol on the 3T3-L1 adipocytes were eligible for this review. Initially, 4361 records were found in the electronic search databases. After removing duplicates and irrelevant studies according to the title and abstract, the full text of the 51 articles was critically screened and 38 in vitro studies were included in this review. Except for one case, all of these studies reported that different doses (ranged 1–200 μM) of resveratrol treatment have anti-obesity effects on 3T3L1 adipocytes through various mechanisms such as induction of apoptosis, a decrease of fat accumulation and adipogenesis, promotion of white adipocytes browning, inhibition of preadipocyte proliferation and consequent differentiation, and up-regulation of miRNA that involved in the antiadipogenic and triacylglycerol metabolism in white adipose tissue. The findings indicate that resveratrol has anti-obesity effects. Therefore, resveratrol treatment could be used to prevent and treat obesity and its related disorders. Well-designed randomized clinical trials with different doses of resveratrol are recommended to be performed on obese subjects.
References
1 . Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017;377(1):13–27.
2 Resveratrol promotes white adipocytes browning and improves metabolic disorders in Sirt1-dependent manner in mice. FASEB J. 2020;34(3):4527–39.
3 . Cardiovascular risk and obesity. Diabetol Metab Syndr. 2019;11(1):1–5.
4 . Prevalence of overweight and obesity in the United States, 1999–2004. JAMA. 2006;295(13):1549–55.
5 . Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med. 2003;348(17):1625–38.
6 Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch Intern Med. 2001;161(13):1581–6.
7 . Lifestyle factors and co-morbidities associated with obesity and overweight in Nkonkobe Municipality of the Eastern Cape, South Africa. J Health Popul Nutr. 2017;36(1):1–8.
8 . Overweight and obesity: prevalence, consequences, and causes of a growing public health problem. Curr Obes Rep. 2015;4(3):363–70.
9 Tea catechin suppresses adipocyte differentiation accompanied by down-regulation of PPARγ2 and C/EBPα in 3T3-L1 cells. Biosci Biotechnol Biochem. 2004;68(11):2353–9.
10 . 3T3-L1 adipocytes display phenotypic characteristics of multiple adipocyte lineages. adipocyte. 2015;4(4):295–302.
11 . Resveratrol metabolites modify adipokine expression and secretion in 3T3-L1 pre-adipocytes and mature adipocytes. PLoS One. 2013;8(5):e63918.
12 Resveratrol attenuates triglyceride accumulation associated with upregulation of Sirt1 and lipoprotein lipase in 3T3-L1 adipocytes. Mol Genet Metab Rep. 2017;12:44–50.
13 Cocoa tea (Camellia ptilophylla) water extract inhibits adipocyte differentiation in mouse 3T3-L1 preadipocytes. Sci Rep. 2016;6(1):1–1.
14 Hypertrophy and/or hyperplasia: dynamics of adipose tissue growth. PLoS Comput Biol. 2009;5(3):e1000324.
15 Berberine suppresses adipocyte differentiation via decreasing CREB transcriptional activity. PLoS One. 2015;10(4):e0125667.
16 . The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009;9(1):1–20.
17 . Anti-obesity drugs: a review about their effects and safety. Diabetes Metab J. 2012;36(1):13–25.
18 . Understanding adipocyte differentiation. Physiol Rev. 1998;78(3):783–809.
19 . Resveratrol exerts anti-obesity effects in high-fat diet obese mice and displays differential dosage effects on cytotoxicity, differentiation, and lipolysis in 3T3-L1 cells. Endocr J. 2016;63(2):169–78.
20 . The effects of resveratrol in the treatment of metabolic syndrome. Int J Mol Sci. 2019;20(3):535.
21 . A perspective on chemoprevention by resveratrol in head and neck squamous cell carcinoma. Adv Exp Med Biol. 2015;815:333–48.
22 . Resveratrol induces chemosensitization to 5-fluorouracil through up-regulation of intercellular junctions, Epithelial-to-mesenchymal transition and apoptosis in colorectal cancer. Biochem Pharmacol. 2015;98(1):51–68.
23 Resveratrol suppresses TPA-induced matrix metalloproteinase-9 expression through the inhibition of MAPK pathways in oral cancer cells. J Oral Pathol Med. 2015;44(9):699–706.
24 AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes. 2010;59(3):554–63.
25 Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell metab. 2011;14(5):612–22.
26 . Implications of resveratrol in obesity and insulin resistance: a state-of-the-art review. Nutrients. 2022;14(14):2870.
27 Resveratrol ameliorates endothelial dysfunction in diabetic and obese mice through sirtuin 1 and peroxisome proliferator-activated receptor δ. Pharmacol Res. 2019;139:384–94.
28 Resveratrol induces Sirt1-dependent apoptosis in 3T3-L1 preadipocytes by activating AMPK and suppressing AKT activity and survivin expression. J Nutr Biochem. 2012;23(9):1100–12.
29 The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1–34.
30 Guidance on assessing the methodological and reporting quality of toxicologically relevant studies: A scoping review. Environ Int. 2016;92:630–46.
31 The size-dependent cytotoxicity of amorphous silica nanoparticles: a systematic review of in vitro studies. Int J Nanomedicine. 2020;15:9089.
32 The effects of resveratrol intake on weight loss: a systematic review and meta-analysis of randomized controlled trials. Crit Rev Food Sci Nutr. 2020;60(3):375–90.
33 . Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature. 2003;425(6954):191–6.
34 . Is the use of resveratrol in the treatment and prevention of obesity premature? Nutr Res Rev. 2009;22(2):111–7.
35 Dose response biology of resveratrol in obesity. J Cell Commun Signal. 2014;8(4):385–91.
36 . Resveratrol in metabolic health: an overview of the current evidence and perspectives. Ann N Y Acad Sci. 2013;1290(1):74–82.
37 Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res. 2010;70(22):9003–11.
38 . The Sir2 family of protein deacetylases. Annu Rev Biochem. 2004;73(1):417–35.
39 . Cytoplasm-localized SIRT1 enhances apoptosis. J Cell Physiol. 2007;213(1):88–97.
40 . Caspase-8 and caspase-9 functioned differently at different stages of the cyclic stretch-induced apoptosis in human periodontal ligament cells. PLoS One. 2016;11(12):e0168268.
41 . The use of digitonin-permeabilized mammalian cells for measuring enzyme activities in the course of studies on lipid metabolism. Anal Biochem. 2005;347(1):1–9.
42 . Creatine supplementation increases glucose oxidation and AMPK phosphorylation and reduces lactate production in L6 rat skeletal muscle cells. J Physiol. 2004;555(2):409–21.
43 Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001;108(8):1167–74.
44 . Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer. 2008;8(1):61–70.
45 . CCL2 is a negative regulator of AMP-activated protein kinase to sustain mTOR complex-1 activation, survivin expression, and cell survival in human prostate cancer PC3 cells. Neoplasia. 2009;11(12):1309–17.
46 Protein kinase C δ (PKCδ) splice variants modulate apoptosis pathway in 3T3L1 cells during adipogenesis: identification of PKCδII inhibitor. J Biol Chem. 2013;288(37):26834–46.
47 Insulin promotes neuronal survival via the alternatively spliced protein kinase CδII isoform. J Biol Chem. 2012;287(12):9299–310.
48 . Brown and brite adipocytes: same function, but different origin and response. Biochimie. 2017;138:102–5.
49 Brown remodeling of white adipose tissue by SirT1-dependent deacetylation of Pparγ. Cell. 2012;150(3):620–32.
50 . Dietary polyphenols and their roles in fat browning. J Nutr Biochem. 2019;64:1–2.
51 . Dietary factors promoting brown and beige fat development and thermogenesis. Adv Nutr. 2017;8(3):473–83.
52 Phenolic compounds inhibit 3T3-L1 Adipogenesis Depending On The Stage Of Differentiation And Their Binding Affinity To PPARγ. Molecules (Basel, Switzerland). 2019;24(6):1045.
53 . Antiadipogenic effects and mechanisms of combinations of genistein, epigallocatechin-3-gallate, and/or resveratrol in preadipocytes. J Med Food. 2017;20(2):162–70.
54 Synergistic effects of leucine and resveratrol on insulin sensitivity and fat metabolism in adipocytes and mice. Nutr Metab. 2012;9(1):77.
55 . Inhibitory effects of pinostilbene on adipogenesis in 3T3-L1 adipocytes: a study of possible mechanisms. Int J Mol Sci. 2021;22(24):13446.
56 . Resveratrol induces cell apoptosis in adipocytes via AMPK activation. Biochem Biophys Res Commun. 2015;457(4):608–13.
57 . Resveratrol inhibits cell differentiation in 3T3-L1 adipocytes via activation of AMPK. Can J Physiol Pharmacol. 2011;89(11):793–9.
58 . Potential miRNA involvement in the anti-adipogenic effect of resveratrol and its metabolites. PLoS One. 2017;12(9):e0184875.
59 Involvement of miR-539-5p in the inhibition of de novo lipogenesis induced by resveratrol in white adipose tissue. Food Funct. 2016;7(3):1680–8.
60 . Physiologically achievable doses of resveratrol enhance 3T3-L1 adipocyte differentiation. Eur J Nutr. 2015;54(4):569–79.
61 . Inhibitory effect of (E)-1,2-di(3,5-dimethoxyphenyl)ethene on 3T3-L1 adiopocyte differentiation. Pharmazie. 2010;65(12):903–5.
62 . Resveratrol analog 4-[2-(3,5-dimethoxyphenyl)vinyl]pyridine reduces differentiation of the 3T3-L1 adipocyte. Pharm Biol. 2013;51(1):96–9.
63 . 3,5-dimethoxy-(4-methoxyphenyl)benzamide suppresses adipogenesis in 3T3-L1 cells. Acta Pol Pharm. 2014;71(1):35–8.
64 . Induction of cell apoptosis in 3T3-L1 pre-adipocytes by flavonoids is associated with their antioxidant activity. Mol Nutr Food Res. 2006;50(11):1072–9.
65 . An inhibitory effect of resveratrol in the mitotic clonal expansion and insulin signaling pathway in the early phase of adipogenesis. Nutr Res (New York, NY). 2012;32(8):607–16.
66 . Trans-anethole ameliorates obesity via induction of browning in white adipocytes and activation of brown adipocytes. Biochimie. 2018;151:1–13.
67 Vitisin A inhibits adipocyte differentiation through cell cycle arrest in 3T3-L1 cells. Biochem Biophys Res Commun. 2008;372(1):108–13.
68 . Delipidating effect of resveratrol metabolites in 3T3-L1 adipocytes. Mol Nutr Food Res. 2012;56(10):1559–68.
69 Resveratrol inhibits lipogenesis of 3T3-L1 and SGBS cells by inhibition of insulin signaling and mitochondrial mass increase. Biochim Biophys Acta. 2016;1857(6):643–52.
70 Resveratrol-induced brown fat-like phenotype in 3T3-L1 adipocytes partly via mTOR pathway. Food Nutr Res. 2020;64.
71 . Resveratrol enhances fatty acid oxidation capacity and reduces resistin and retinol-binding protein 4 expression in white adipocytes. J Nutr Biochem. 2011;22(9):828–34.
72 . Screening of potential anti-adipogenic effects of phenolic compounds showing different chemical structure in 3T3-L1 preadipocytes. Food Funct. 2017;8(10):3576–86.
73 . Mechanisms of resveratrol-induced inhibition of clonal expansion and terminal adipogenic differentiation in 3T3-L1 preadipocytes. J Gerontol A Biol Sci Med Sci. 2013;68(11):1356–76.
74 . Effect of resveratrol on mitochondrial activity in differentiated mature adipocytes. Int J Morphol. 2015;33(3):1085–92.
75 Combined effects of genistein, quercetin, and resveratrol in human and 3T3-L1 adipocytes. J Med Food. 2008;11(4):773–83.
76 . Resveratrol induces apoptosis and inhibits adipogenesis in 3T3-L1 adipocytes. Phytother Res: PTR. 2008;22(10):1367–71.
77 . Effects of yerba maté, a plant extract formulation (“YGD”) and resveratrol in 3T3-L1 adipogenesis. Molecules (Basel, Switzerland). 2014;19(10):16909–24.
78 DNA methylation changes are associated with the programming of white adipose tissue browning features by resveratrol and nicotinamide riboside neonatal supplementations in mice. Nutrients. 2020;12(2).
79 Enhanced inhibition of adipogenesis and induction of apoptosis in 3T3-L1 adipocytes with combinations of resveratrol and quercetin. Life Sci. 2008;82(19–20):1032–9.
80 . Resveratrol liposomes and lipid nanocarriers: comparison of characteristics and inducing browning of white adipocytes. Colloids Surf B Biointerfaces. 2018;164:414–23.
81 Metformin and resveratrol ameliorate muscle insulin resistance through preventing lipolysis and inflammation in hypoxic adipose tissue. Cell Signal. 2016;28(9):1401–11.
82 . Anti-obesity effect of resveratrol-amplified grape skin extracts on 3T3-L1 adipocytes differentiation. Nutr Res Pract. 2012;6(4):286–93.
